Stryker Corporation (SYK): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

By
A A A

Summary:
Stryker continues to grow through acquisitions. Though its 2014-second quarter adjusted earnings rose nearly 1.0% year-over-year, it missed the Zacks Consensus Estimate by $0.01. The company expects a 5.0 to 6.0% growth in organic revenues for 2014 as compared with the earlier range of 4.5 to 6%. However, we are concerned about the strong competition from Johnson & Johnson. Further, the merger announcements between Medtronic and Covidien, and between Zimmer Holdings and Biomet pose threat to Stryker from becoming a major medtech company. As a result, we reiterate our Neutral recommendation on Stryker and set a target price of $86.00.

Overview:

Headquartered in Kalamazoo, Mich., Stryker Corporation (SYK) is one of the world's largest medical device companies operating in the global orthopedic market. The company was founded in 1941 and sells its offerings in more than 100 countries worldwide. As such, Stryker currently has three business segments: Reconstructive, MedSurg Equipment, and Neurotechnology and Spine.

The Reconstructive division includes hip, knee, trauma-related products and extremities implant systems. As part of the hip offerings, the company offers a number of products designed to meet the needs of revision hip procedures, including Restoration, Restoration Modular, Trident Acetabular and ADM Mobile Bearing, each of which provides surgeons with the options necessary to address revision surgery challenges. Stryker's knee implant systems include Triathlon, Scorpio, and Global Modular Replacement System (GMRS) systems. The company has several product lines for trauma and extremity implant including Intramedullary (IM) and cephalomedullary nails, locked and non-locked plating, hip fracture solutions, external fixation systems and bone substitutes.

The MedSurg Equipment segment comprises three main divisions: Stryker Instruments (powered surgical tools), Stryker Endoscopy (powered surgical instruments and viewing aids), and Stryker Medical (specialty stretchers).

The new Neurotechnology and Spine division includes the Neurovascular business (Target) acquired from Boston Scientific (BSX), the spinal implant and interventional spine businesses and the Leibinger Unit/Craniomaxillofacial (CMF) unit. The company markets spinal implant products including cervical, thoracolumbar and interbody systems used in spine injury, deformity and degenerative therapies. The neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a comprehensive line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke.


Stryker Corporation (SYK): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

STRYKER CORP (SYK): Free Stock Analysis Report

To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: SYK , IM , BSX , CMF

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

111,864,163
  • $3.91 ▲ 2.36%
76,404,746
  • $7.37 ▼ 5.03%
66,680,057
  • $15.25 ▼ 2.12%
61,293,760
  • $30.55 ▼ 6.09%
56,394,825
    $23 unch
55,005,642
  • $95.60 ▼ 2.60%
47,372,853
  • $95.02 ▼ 2.02%
44,783,481
  • $45.19 ▼ 2.40%
As of 7/31/2014, 04:07 PM